Announcements
- Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
- Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
- Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
- Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
- Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
- Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
- Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
More ▼
Key statistics
As of last trade Bolt Biotherapeutics Inc (6LP:FRA) traded at 0.693, 2.51% above its 52-week low of 0.676, set on Jun 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.694 |
---|---|
High | 0.694 |
Low | 0.693 |
Bid | 0.686 |
Offer | 0.713 |
Previous close | 0.683 |
Average volume | 0.00 |
---|---|
Shares outstanding | 38.13m |
Free float | 36.80m |
P/E (TTM) | -- |
Market cap | 28.71m USD |
EPS (TTM) | -1.66 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 08:59 BST.
More ▼